Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
In a phase II basket trial, the BRAF inhibitor vemurafenib showed preliminary evidence of efficacy in 13 BRAF-mutant non-melanoma tumor types, including some typically considered treatment refractory.